Cyclotides as immunosuppressive agents
AssigneesUniversitatsklinikum Freiburg, Medizinische Universität Wien
InventorsChristian Werner Gruber, Carsten Gruendemann
Life of this patent
Estimating the term…
Loading patent…
AssigneesUniversitatsklinikum Freiburg, Medizinische Universität Wien
InventorsChristian Werner Gruber, Carsten Gruendemann
Estimating the term…
The present invention relates to a pharmaceutical composition comprising a cyclotide for use in immune suppression as well as to a method for immune suppression comprising the step of administering an effective amount of a pharmaceutical composition comprising such a cyclotide to a subject in need thereof. The present invention also relates to a pharmaceutical composition comprising a cyclotide for use in treating or preventing a disorder selected from the group consisting of (i) an autoimmune disorder; (ii) a hypersensitivity disorder; and (iii) a lymphocyte-mediated inflammation. Likewise, the present invention also relates to a method for treating or preventing a disorder selected from the group consisting of (i) an autoimmune disorder; (ii) a hypersensitivity disorder; and (iii) a lymphocyte-mediated inflammation. The present invention further relates to a method of screening for and/or selecting an immunosuppressive cyclotide or a mutation which results in a mutated cyclotide having an induced or enhanced immunosuppressive activity. The present invention further relates to a method of producing an immunosuppressive cyclotide or an immunosuppressive pharmaceutical composition. The present invention further relates to a mutated cyclotide having immunosuppressive activity and a pharmaceutical composition comprising the same.
1-35. (canceled)
A method for immunosuppression, the method comprising administering an effective amount of a non-grafted cyclotide to a subject in need thereof, wherein said cyclotide comprises a head-to tail cyclized peptide, wherein said head-to tail cyclized peptide comprises six conserved cysteine residues capable to form three disulfide bonds arranged in a cyclic cystine-knot (CCK) motif.
The method of claim 16, wherein said additional immunosuppressant comprises Cyclosporine A, Muromonab-CD3 or Basiliximab.
Method of screening for and/or selecting an immunosuppressive cyclotide, the method comprising:
A mutated cyclotide having immunosuppressive activity, said cyclotide comprising:
Dependencies are inferred from the claim text.